Cal Cohen

CRI of New England 23 Miner Street Boston, MA 02215-3319 Fax: +1 617 778 5456 ccohen@crine.org

Efficacy and safety results at 48 weeks with the novel NNRTI, TMCI25, and impact of baseline resistance on the virologic response in study **TMCI25-C223**

Abstract

Methods

TMC125-C223 is a randomized, controlled study of TMC125 in 199 patients with documented NNRTI resistance and $\geq\!\!3$ primary protease inhibitor (PI) mutations. Patients were randomized to TMC125 (400mg or 800mg bid) with an investigator selected background, or standard-of-care control regimen

Results

Median baseline viral load (VL) was 4.7 log₁₀ copies/mL and CD4 count 100 cells/mm³. At 48 weeks, the mean reduction in log₁₀ VL (intent-to-treat (ITT), non-completer = failure) was -0.88, -1.01 and -0.14 for the 400mg, 800mg and control arms, respectively, the difference for both TMC125 doses versus control was statistically significant (p<0.05). CD4 cell counts increased by 58, 61 and 13 for the 400mg, 800mg and control arms, respectively.


Virologic failure on both TMC125 arms was 9%; in the control arm, 98% of patients discontinued study, 78% due to virologic failure. The comparison of safety was confounded by the lower median duration of treatment in the control arm of 17.9 weeks, versus 47.7 weeks in both TMC125 groups. Grade 3 and 4 adverse events (AEs) (all causes) were reported in 43% of patients on TMC125; 17% discontinued due to AEs. At baseline, patients had a median of two NNRTI mutations and the phenotypic median fold-change (FC) to efavirenz, nevirapine and TMC125 was 41, 61, and 1.7, respectively

The virologic response by number of NNRTI mutations at baseline is shown for the 800mg group (dose selected for Phase III development as new 200mg formulation).


No. of mutations	0	1	2	≥3
N (%)	14 (18%)	19 (24%)	l 6 (20%)	30 (38%)
Mean Δ VL	-1.67	-1.38	-0.90	-0.54

Conclusions


In this study, TMC125 showed high rates of sustained efficacy at 48 weeks in heavily pretreated patients. The analysis of response by baseline resistance shows that TMC125 retains activity in the presence of multiple NNRTI mutations where current NNRTIs are not expected to be effective.











TMC125-C223: safety - overview

Safety comparisons confounded due to high rate of treatment discontinuations in control group, leading to substantial difference in treatment durations between groups

 AEs reported in 99% in TMC125 groups and 78% in control Both TMC125 doses were equally well tolerated

Most common AEs, n (%)	All TMC125 (n=159)	Active control (n=40)
Median treatment duration	48 weeks	18 weeks
Diarrhea	35 (22)	6 (15)
Any rash	32 (20)	3 (8)
Injection-site reaction	32 (20)	10 (25)
Pyrexia	32 (20)	4 (10)
Fatigue	25 (16)	6 (15)
Headache	25 (16)	2 (5)
Nausea	24 (15)	6 (15)
Lymphadenopathy	22 (14)	4 (10)
Insomnia	21 (13)	4 (10)

	All TMC125	Active control
AEs, n (%)	(n=159)	(n=40)
Median treatment duration	48 weeks	18 weeks
Any grade 3	62 (39)	9 (23)
Any grade 4	21 (13)	5 (13)
 Specific grade 3/4 AEs in ≥3 pneumonia: four patients abdominal pain: three patients drug-related rash: three patients hypertriglyceridemia: three patients 	s nts; no grade 4 rash v	vas seen

control one death (cardiopulmonary failure and myocardial infarction [MI]) in 400mg bid group considered possibly related to TMC125

TMC125-C223:	laboratory	abnormalities
--------------	------------	---------------

Laboratory parameters, n (%)	All TMC125 (n=159)	Active control (n=40)
Median treatment duration	48 weeks	18 weeks
Any grade 3/4 abnormality	62 (39)	14 (35)
Any grade 3 abnormality	57 (36)	13 (33)
Any grade 4 abnormality	17 (11)	6 (15)

- No dose difference for any laboratory abnormality
- Most common grade 3/4 laboratory abnormalities for TMC125 and active control were
- triglycerides: 14 (9%) and 4 (11%) patients
- pancreatic amylase: 13 (8%) and zero patients
- neutropenia: 12 (8%) and 4 (11%) patients
- creatinine: 6 (4%) and zero patients

TMC125-C223: safety - serious adverse events (SAEs)

SAEs were reported in 27% in the TMC125 groups with no dose

n=5 n=4 n=3 n=2 n=1 n=0* NNRTI resistance-associated mutations 3.8 7.5 80 21.5 21.5 27.5 60 21.5 27.8 40 35.0 22.8 24.1 17.5 19.0 10.1 5.0 800mg bid 400mg bio Control Treatment group Most frequent mutations: K103N, Y181C and G190A *All patients had at least one NNRTI mutation at screening or from prior genotyping TMC125-C223: baseline resistance - phenotype 100.00 TMC125 10.000 1.000 100 10 ç 0.1 ≥3 Number of baseline NNRTI m utation **Baseline NNRTI mutations associated with a** TMC125 FC >10 (arbitrary threshold) The geometric mean FC to TMC125 for each NNRTI mutation present at baseline was determined There was no single NNRTI mutation that was associated with a mean FC >10 (arbitrary threshold) to TMC125
 clinically relevant FC to be determined from larger data sets Frequency of combinations of NNRTI mutations associated with a mean TMC125 FC >10 was low (12%) Each of the following mutations, always in combination with up to four other mutations, were associated with a mean FC >10• K101P, V179E, V179F, Y181I, Y181V, G190S, M230L for V179E, V179F, G190S or M230L: the additional mutations always included Y181C when the FC >10 • These mutations were previously identified in vitro to be associated with an increased FC to TMC125 oets J, et al. J Virol 2005;79:12773-82 1. Ving TMC125-C223: number of NNRTI mutations and virologic response at Week 48 TMC125 **Baseline NNRTI mutations** in TMC125 800mg bid Active bid control n=40 -0.14 -0.5 -1.0 -1.01 -1.5 -1.38 1.67 -2.0 Patients discontinuing the trial for any reason had their VL response imputed as no change from baseline (NC=F)
 'All patients had NNRTI mutations from prior genotyping Conclusions

TMC125-C223: baseline resistance – genotype

Efficacy and safety

- In this study, TMC125 showed high rates of sustained efficacy at 48 weeks in heavily pretreated patients.
- There were no dose-related effects on safety and tolerability.
- TMC125 retains activity in the presence of multiple NNRTI mutations where current NNRTIs are not expected to be effective.

Baseline resistance and VL response

- Baseline FC to TMC125 in this highly treatment-experienced population was low and increased with higher number of NNRTI mutations.
- There was no single NNRTI mutation that was associated with a FC > 10 (arbitrary threshold) to TMC125.

Poster No. TUPE0061

≥3

-0.54

		TMC125		
System organ class, preferred term n (%)	400mg bid (n=80)	800mg bid (n=79)	All TMC125 (n=159)	Control (n=40)
Any SAE	21 (26)	22 (28)	43 (27)	7 (18)
Blood and lymphatic system disorders Pancytopenia	1 (1)	1 (1)*	2 (1)	0
Cardiac disorders Cardiopulmonary failure MI	1 (1)* 2 (3)†	0	1 (1) 2 (1)	0
Nervous system disorders Hemorrhagic stroke	1 (1)*	0	1 (1)	0
*Possibly related to TMC125; †one	case possibly relat	ed; one case not	related	

- Investigate baseline resistance parameters
- genotype phenotype
- mutations associated with increased baseline
- FC in EC_{co} values to TMC125
- ITT analysis, all patients included
- Investigate virologic response associated with the number of baseline NNRTI mutations
- imputed (NC=F) data
- only the TMC125 800mg bid was included (comparable to the 200mg bid dose of the new formulation used in the Phase III studies)

- The mean change in VL in the TMC125 800mg bid group (imputed data) was
- 0.90 log_10 or greater in patients with ${\leq}2$ NNRTI mutations
- 0.54 \log_{10} in patients with three or more NNRTI mutations.

Acknowledgments

Many thanks to the patients who participated in the study, the study center staff, Tibotec study personnel, Virco and the principal investigators

Dr B Barnett	Dr M Fischl	Dr N Markowitz	Dr M Saag
Dr J Baxter	Dr J Gallant	Dr D Mildvan	Dr J Sampson
Dr S Becker	Dr J Gathe	Dr S Miles	Dr K Sathasivam
Dr T Bell	Dr R Greenberg	Dr A Mills	Dr S Schrader
Dr D Berger	Dr H Grossman	Dr A Morris	Dr L Schwartz
Dr G Blick	Dr F Haas	Dr R Murphy	Dr P Shalit
Dr C Borkert	Dr C Hicks	Dr R Myers	Dr S Smith
Dr S Brown	Dr D Jayaweera	Dr J Nadler	Dr C Steinhart
Dr T Campbell	Dr H Kessler	Dr R Nahass	Dr R Stryker
Dr P Cimoch	Dr H Khanlou	Dr R Pollard	Dr P Tebas
Dr C Cohen	Dr J Leider	Dr R Reichman	Dr M Thompson
Dr E DeJesus	Dr D Margolis	Dr P Ruane	Dr D Ward